Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study

BACKGROUND: (Pre)clinical evidence is accumulating that intermittent exposure to increased doses of protein kinase inhibitors may improve their treatment benefit. In this phase I trial, the safety of high-dose, pulsatile sorafenib was studied. PATIENTS AND METHODS: High-dose sorafenib was administer...

Descripción completa

Detalles Bibliográficos
Autores principales: Mammatas, L. H., Zandvliet, A. S., Rovithi, M., Honeywell, R. J., Swart, E. L., Peters, G. J., Menke-van der Houven van Oordt, C. W., Verheul, H. M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188706/
https://www.ncbi.nlm.nih.gov/pubmed/32274565
http://dx.doi.org/10.1007/s00280-020-04065-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188706/
https://www.ncbi.nlm.nih.gov/pubmed/32274565
http://dx.doi.org/10.1007/s00280-020-04065-5

Ejemplares similares